Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Ziekten en gezondheid in kaart brengen
Kwaliteit van de gezondheidszorg
Downloaden 2.05 MBAuteurs
M. Arbyn [3]; L Xu [4]; Cindy Simoens [5]; Martin-Hirsch, Pierre Pl [6]; Bryant, Andrew [7]; Beutels, Philippe [8]; Paraskevaidis, Evangelos [9]; van Hoof, Elke [10]; Steben, Marc [11]; Qiao, Youlin [12]; Zhao, Fang-Hui [13]; Schneider, Achim [14]; Kaufmann, Andreas [15]; Dillner, Joakim [16]; Markowitz, Lauri [17]; Hildesheim, Allan [18]Trefwoorden
Samenvatting:
This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will asses…